Skip to Main Content

Clinical Studies and Protocols

Site Map Investigators Log-in
(RDA-0269) Tumor immunity in neurologically normal patients


 Return to List of Clinical Studies
 Return to List of Protocols for Cancer
Tumor immunity in neurologically normal patients (RDA-0269)

Principal Investigator:
Robert B. Darnell M.D., Ph.D.

Investigators:
Robert B. Darnell M.D., Ph.D.

Contact Information:
Mayu Frank, ANP
Rockefeller University
1230 York Avenue
New York, NY 10065
Telephone: 212-327-7443
Email: frankm@rockefeller.edu
Enrollment Status:
Open to Enrollment

Brief Summary of Protocol:
Paraneoplastic neurologic disorders (PNDs) are diseases which occur in some cancer patients, and are thought to arise when cancer cells produce proteins that are normally produced only in nerve cells. The patient’s immune system fights the cancer cells, but because the proteins the cancer cells produce are the same as the proteins in certain nerve cells, the immune system mistakenly attacks the nerve cells. This misdirected immune attack is thought to cause the neurologic problems in patients with PNDs, such as difficulty walking and speaking, abnormal and decreased sensations, and poor memory.

The reasons for doing this research is to compare immune cells and serum (the fluid part of your blood) taken from normal volunteers to those with PND and those with other kinds of cancers, so that we can better understand that disease. The research involves determining whether there are immune cells capable of recognizing and killing tumor cells circulating in the blood of PND patients, patients with other kinds of cancer, and normal volunteers.



Detailed Description of Protocol:




What specifically makes a person eligible for the study?
You may be eligible to enter this study:


- PND Patient

OR

- Cancer Patient

OR

- Healthy Volunteer

Gender:
Both

Age(s):
18 years and older

Children permitted to participate:
No

Potential Benefits.....
There is no direct benefit to you for participating in this study. The investigators of this study may gain new knowledge and information from your participation in this study that may benefit others with cancers in the future.



Compensation:
There is no cost to you for being in this research study.

We will give you $25 if you participate only in the first visit.

We will give you a total of $300 if you participate in the leukapheresis to help pay for your costs or time spent being in this research study.